Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
Concurring Statement of Commissioner Joshua D. Wright - In the Matter of Ferrellgas Partners, L.P.
Lakshmi Infosoul Services Pvt Ltd.
Zeal IT Solutions Pvt Ltd., et al.
PDB Sports, Ltd., d/b/a Denver Broncos Football Club, In the Matter of
Concurring Statement of Commissioner Joshua D. Wright In the Matter of i-Health, Inc. and Martek Biosciences Corporation
Commission Letter From Jessica L. Rich, Director of the Bureau of Consumer Protection, Filed With the Bankruptcy Court for the Southern District of New York -- in In re ConnectEDU, Inc., No. 14-11238 (Bankr. S.D.N.Y.)
Dissenting Statement of Commissioner Joshua D. Wright - In the Matter of McWane, Inc., a corporation, and Star Pipe Products, Ltd
Dissenting Statement of Commissioner Joshua D. Wright
Mylan Inc., Agila Specialties Global Pte.Limited, Agila Specialties Private Limited, and Strides Arcolab Limited, In the Matter of
Under a settlement with th FTC, Mylan, Inc., and Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. (collectively, Agila) divested 11 generic injectable drugs as a condition of allowing Mylan’s proposed acquisition of Agila from Strides Arcolab Ltd. (Strides). According to the complaint, in each of these 11 markets, Mylan and Agila are two of only a limited number of current or likely future competitors. The number of suppliers in generic pharmaceutical markets matters because prices generally decrease as the number of competing generic suppliers increases. In addition, the injectable generic products of concern are highly susceptible to supply disruptions caused by the inherent difficulties of producing sterile liquid drugs.